Compare GSK plc (GSK) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while iShares 7-10 Year Treasury Bond ETF trades at $93.56. The key difference: GSK plc pays a 3.49% dividend while iShares 7-10 Year Treasury Bond ETF pays none, and GSK plc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | IEF | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $97.99 |
52-Week Low | $36.20 | $93.11 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
IEF, the iShares 7-10 Year Treasury Bond ETF, trades at $93.56, showing minimal daily change. The technical outlook is bearish, with moving averages signaling a downtrend and price near key support at $93. Recent news highlights a surge in bond ETF inflows as investors seek yield amid market volatility and uncertainty over Federal Reserve policy, with over $100 billion flowing into cash-like ETFs according to Benzinga on July 14, 2026.
The outlook is dominated by interest rate risk, with market sentiment cautious as debates over potential Fed hikes persist. Key opportunities include the ETF's role as a core fixed-income holding for duration exposure, while primary risks are further rate increases that would pressure bond prices and the ETF's net asset value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
